CCIA
RAPT

Campbell & Co Investment Adviser’s RAPT Therapeutics RAPT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,652
Closed -$328K – 1328
2023
Q4 		$328K Buy
+1,652
New +$204K 0.03% 883

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Campbell & Co Investment Adviser's RAPT Position: Q1 2024 in Review

Campbell & Co Investment Adviser sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 1,652 shares — an estimated $328K sold.

Campbell & Co Investment Adviser first reported a position in RAPT in Q4 2023 and held it in 1 quarter. The position peaked at $328K in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • Campbell & Co Investment Adviser reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 1,652 RAPT Therapeutics shares in Q1 2024, an estimated $328K.
  • Campbell & Co Investment Adviser first reported a position in RAPT Therapeutics in Q4 2023 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's RAPT Therapeutics position peaked at $328K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2024, filed 10 May 2024.